Takeda terminates plans for Vaxem Hib launch in Japan
Discontinuation due to the vaccine supplier’s (GSK) decision to discontinue global production.
Takeda Pharmaceutical has announced the cancellation of its planned launch in Japan of Vaxem Hib, a conjugate vaccine to prevent infections caused by Haemophilus influenzae type b (Hib). This is the result of the discontinuation of the manufacture and supply of Vaxem Hib worldwide by the manufacturer GlaxoSmithKline (GSK) as part of an ongoing process by GSK to optimize its worldwide manufacturing footprint. This decision is accompanied by the termination of the distribution agreement with Takeda for Japan and discontinue manufacturing and supply of VAXEM Hib® to Takeda. GSK is the only supplier of this vaccine to Takeda.
In January 2016, the Japanese Ministry of Health, Labour and Welfare approved Takeda’s New Drug Application (NDA) for Vaxem Hib in children aged from 2 months to under 5 years of age, to prevent infections caused by Hib.
Takeda developed the vaccine for Japan in collaboration with Novartis and then GSK, following GSK’s acquisition of Novartis’ vaccine business in March 2015. Takeda had planned to launch the vaccine in Japan in early 2017. GSK recently made the decision to terminate global production and supply of Vaxem Hib, and subsequently informed Takeda of this decision. Takeda proposed alternatives to GSK to allow the launch of Vaxem Hib to proceed as planned, but GSK deemed these options unfeasible.
Takeda remains dedicated to protecting the health of the Japanese population through the provision of important vaccines. Takeda will maintain its focus on vaccine development programs against significant infectious diseases such as dengue, zika, norovirus and polio.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.